Loading
PDBj
メニューPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6CCV

Crystal structure of a Mycobacterium smegmatis RNA polymerase transcription initiation complex with inhibitor Rifampicin

6CCV の概要
エントリーDOI10.2210/pdb6ccv/pdb
分子名称DNA-directed RNA polymerase subunit alpha, SULFATE ION, 1,2-ETHANEDIOL, ... (15 entities in total)
機能のキーワードdna-directed rna polymerase tuberculosis inhibitor antibiotic transcription initiation, transcription
由来する生物種Mycobacterium smegmatis (strain ATCC 700084 / mc(2)155)
詳細
タンパク質・核酸の鎖数11
化学式量合計487274.79
構造登録者
Lilic, M.,Darst, S.A.,Campbell, E.A. (登録日: 2018-02-07, 公開日: 2018-08-15, 最終更新日: 2023-10-04)
主引用文献Peek, J.,Lilic, M.,Montiel, D.,Milshteyn, A.,Woodworth, I.,Biggins, J.B.,Ternei, M.A.,Calle, P.Y.,Danziger, M.,Warrier, T.,Saito, K.,Braffman, N.,Fay, A.,Glickman, M.S.,Darst, S.A.,Campbell, E.A.,Brady, S.F.
Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism.
Nat Commun, 9:4147-4147, 2018
Cited by
PubMed Abstract: Rifamycin antibiotics (Rifs) target bacterial RNA polymerases (RNAPs) and are widely used to treat infections including tuberculosis. The utility of these compounds is threatened by the increasing incidence of resistance (Rif). As resistance mechanisms found in clinical settings may also occur in natural environments, here we postulated that bacteria could have evolved to produce rifamycin congeners active against clinically relevant resistance phenotypes. We survey soil metagenomes and identify a tailoring enzyme-rich family of gene clusters encoding biosynthesis of rifamycin congeners (kanglemycins, Kangs) with potent in vivo and in vitro activity against the most common clinically relevant Rif mutations. Our structural and mechanistic analyses reveal the basis for Kang inhibition of Rif RNAP. Unlike Rifs, Kangs function through a mechanism that includes interfering with 5'-initiating substrate binding. Our results suggest that examining soil microbiomes for new analogues of clinically used antibiotics may uncover metabolites capable of circumventing clinically important resistance mechanisms.
PubMed: 30297823
DOI: 10.1038/s41467-018-06587-2
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (3.05 Å)
構造検証レポート
Validation report summary of 6ccv
検証レポート(詳細版)ダウンロードをダウンロード

227111

件を2024-11-06に公開中

PDB statisticsPDBj update infoContact PDBjnumon